Niraparib with immunotherapy maintenance for advanced small-cell lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether adding niraparib (a pill cancer medicine) to ongoing immunotherapy maintenance can help people with advanced small-cell lung cancer live longer or better. It is for tumors that show a specific protein marker (SLFN11) and that did not worsen after standard first-line chemo-immunotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have stage IV extensive small-cell lung cancer confirmed by biopsy or fluid sample.
- Your tumor tissue must be available and tested for SLFN11, and at least 20% of tumor cells must show the protein.
- You must have finished 4 cycles of first-line chemo plus an anti-PD-L1 antibody (atezolizumab or durvalumab) and your cancer must not have worsened during or after treatment.
- You must be able to continue immune maintenance treatment (immunotherapy) going forward.
- Your blood counts and organ function (kidney/liver) must be adequate, and your general function score must be 0–2.
- You must be 18 or older, and if you can become pregnant you need a negative pregnancy test and reliable birth control during and after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether combining pembrolizumab and olaparib can improve outcomes in people with extensive-stage small cell lung cancer. It mainly aims to shrink tumors and help control the cancer for longer.
This trial tests different experimental drugs matched to the specific genetic makeup of your small cell lung cancer. The goal is to see if targeting your cancer's particular molecular type can shrink tumors or delay their growth better than standard care.
This trial tests a combination of golidocitinib (a targeted pill) and a PD-1 inhibitor (a type of immunotherapy) as a maintenance treatment after initial chemotherapy. It may help keep your lung cancer from growing longer.
This trial tests a combination of low-dose radiation, an immunotherapy drug (sugemalimab), chemotherapy, and a targeted drug (olaparib) as a first treatment for people with extensive-stage small cell lung cancer that has a specific marker called SLFN-11. The goal is to see if this combination is safe and works better than standard treatment.
This trial tests a combination of drugs as a maintenance therapy after initial chemotherapy for extensive-stage small cell lung cancer. It aims to see if this combination can help keep the cancer from growing.
This trial is testing whether a maintenance therapy using anlotinib (a drug that blocks blood vessel growth) combined with immunotherapy can help keep extensive-stage small cell lung cancer from progressing after initial chemoimmunotherapy. It aims to see if this reduces the chance of the cancer coming back and improves survival.
Hear when a new SCLC,Extensive Stage trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.